The Cancer Immunology Immunotherapy is a research journal that publishes research in the field of Oncology | Immunology. This journal is published by the SPRINGER. The ISSN of this journal is 0340-7004.
Also, please check the following important details about cancer immunology immunotherapy: Publisher, ISSN, Ranking, Indexing, Impact Factor (if applicable), Publication fee (APC), Review Time, and Acceptance Rate.
According to Clarivate's JCR, journals indexed in SCIE/SSCI have an impact factor.
The ISSN (International Standard Serial Number) is an 8-digit code used to uniquely identify journals. ISSN numbers are assigned by a network of ISSN National Centres, usually located at national libraries and coordinated by the ISSN International Centre based in Paris. The International Centre is an intergovernmental organization created in 1974 through an agreement between UNESCO and the French government.
Journal Title: | CANCER IMMUNOLOGY IMMUNOTHERAPY |
Publisher: | SPRINGER |
ISSN: | 0340-7004 |
E-ISSN: | 1432-0851 |
Language: | English |
Country of Publisher: | ONE NEW YORK PLAZA, SUITE 4600 , NEW YORK, United States, NY, 10004 |
Subject: | Oncology | Immunology |
The cancer immunology immunotherapy is indexed in:
An indexed journal means that the journal has gone through and passed a review process of certain requirements done by a journal indexer.
The Web of Science Core Collection includes the Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts & Humanities Citation Index (AHCI), and Emerging Sources Citation Index (ESCI).
The latest impact factor of cancer immunology immunotherapy is 4.6 which is recently updated in June, 2024.
The impact factor (IF) is a measure of the frequency with which the average article in a journal has been cited in a particular year. It is used to measure the importance or rank of a journal by calculating the times it's articles are cited.
Note: Every year, The Clarivate releases the Journal Citation Report (JCR). The JCR provides information about academic journals including impact factor. The latest JCR was released in June, 2023. The JCR 2024 will be released in the June 2024.
The publication time may vary depending on factors such as the complexity of the research and the current workload of the editorial team. Journals typically request reviewers to submit their reviews within 3-4 weeks. However, some journals lack mechanisms to enforce this deadline, making it difficult to predict the duration of the peer review process.
The review time also depends upon the quality of the research paper.
Visit to the official website of the journal/ conference to check the details about call for papers.
If your research is related to Oncology | Immunology, then visit the official website of cancer immunology immunotherapy and send your manuscript.
SIMILIAR JOURNALS
CANCER IMMUNOLOGY IMMUNOTHERAPY
ISSN: 0340-7004JOURNAL FOR IMMUNOTHERAPY OF CANCER
ISSN:TOP RESEARCH JOURNALS